AKT1 and metabolic syndrome: Disruption of the insulin signaling cascade—particularly the phosphoinositide 3-kinase (PI3K)/AKT pathway—leads to a cascade of metabolic disturbances, including hyperglycemia, dyslipidemia, and chronic inflammation [97,98].